 Biomica released impressive pre-clinical data for its rationally designed 4 strand microbiome therapeutic candidate BMC128 in immuno-oncology presented at the 5th Annual European Microbiome Drug Development conference on January 28. BMC128 is expected to be tested in human clinical trials in Israel during the second half of this year. 